Optimising the Aerodynamic Performance of Spray Dried mRNA Lipoplexes in Mannitol or Lactose Matrix
![Optimising the Aerodynamic Performance of Spray Dried mRNA Lipoplexes in Mannitol or Lactose Matrix](https://www.pharmaexcipients.com/wp-content/uploads/2024/08/Optimising-the-Aerodynamic-Performance-of-Spray-Dried-mRNA-Lipoplexes-in-Mannitol-or-Lactose-Matrix.jpg)
Introduction
- Many respiratory pathogens enter the body through the respiratory tract, the lungs and the mucosal immune system are promising targets for therapeutic interventions.
- Liquid vaccines face the risk of chemical degradation and physical instability
-> Solid formulations can secure stability without challenging storage conditions. Since spray drying offers continuous manufacturing with high production capacity, we chose spray drying as production technique.
Objective
Formulation of an Inhalable Dry Powder Platform for mRNA Therapeutics
![Formulation of an Inhalable Dry Powder Platform for mRNA Therapeutics](https://www.pharmaexcipients.com/wp-content/uploads/2024/08/Formulation-of-an-Inhalable-Dry-Powder-300x150.jpg)
Previous Work:
- Spray drying at an outlet temperature of 50°C in mannitol matrix
→ efficient transfection- Aerodynamic assessment of the formulation exhibited a FPF (fine particle fraction, aerodynamic diameter < 5 µm) of 35% and a powder residue of 22% in the capsules.
-> Optimisation of Aerodynamic Performance and Increasing Detachment by Co-Spray Drying with L-leucine
See the full poster on “mRNA Lipoplexes” here
(click the picture to download the poster)
Source: MEGGLE poster “mRNA Lipoplexes”, MEGGLE Excipients and the University of Kiel have joined forces to shed light on this interesting topic, Jana Schembera, Ricarda Leister, Constanze Müller, Regina Scherließ
Do you need more information or a sample of MEGGLE excipients?